Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC

February 21st 2025

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm

February 19th 2025

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

Nadofaragene Firadenovec Trial Looks to Prove Efficacy in Intermediate-Risk NMIBC

February 19th 2025

Following its approval in high-risk BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec is being assessed in intermediate-risk disease in ABLE-32.

The Heart of the Matter: Unraveling the Link Between CVD and Breast Cancer for American Heart Month

February 18th 2025

Amy M. Ahnert, MD, highlights newer shared risk factors for CVD and breast cancer and questions regarding personalized screening for the diseases.

A Cardiologist Highlights the Interwoven Elements of CVD and Breast Cancer

February 17th 2025

Amy M. Ahnert, MD, details the significance of findings on the link between CVD and breast cancer as well as next steps to further define the connection.

Investigators Look to Add Duvelisib to Treatment Arsenal of Rare T-Cell Lymphoma Subtype

February 17th 2025

Christopher P. Fox, PhD, discusses the upcoming phase 3 TERZO trial of duvelisib in patients with nodal T-cell lymphoma with follicular helper T phenotype.

Avutometinib/Defactinib Combo Could Fill Sizeable Unmet Need in LGSOC

February 17th 2025

Ritu Salani, MD, MBA, details the significance of trials examining avutometinib plus defactinib and enthusiasm for ADCs in ovarian cancer.

Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant

February 16th 2025

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies

February 16th 2025

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC

February 15th 2025

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies

February 15th 2025

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status

February 14th 2025

Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.

Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024

February 14th 2025

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC

February 14th 2025

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.

Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC

February 13th 2025

A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.

FDA Grants Orphan Drug Designation to OPN-6602 for R/R Multiple Myeloma

February 13th 2025

OPN-6602, a small molecule EP300/CBP inhibitor, received orphan drug designation for multiple myeloma.

Illuccix PSMA-PET Imaging Agent Receives UK Approval in Prostate Cancer

February 13th 2025

The UK Medicines and Healthcare Products Regulatory Agency has approved the kit for the preparation of gallium-68 gozetotide injection.

2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward

February 13th 2025

Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.

NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines

February 12th 2025

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

FDA Grants Fast Track Designation to CUSP06 for Platinum-Resistant Ovarian Cancer

February 12th 2025

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.